Experience with cefotaxime in gynecology and obstetrics.
Minimal inhibitory concentrations of cefotaxime, determined against clinical isolates from gynecological and obstetrical infections, were less than or equal to 1.56 microgram/ml against about 65% of the aerobes tested. Against anaerobic organisms, the growth of about 65% of the strains was inhibited by less than or equal to 12.5 microgram/ml. The passage of cefotaxime into human uterine tissue was investigated after a single 1-gm intravenous (IV) injection. Peak concentration of 12.24 microgram/gm was attained after about 20 minutes. Passage to the pelvic cavity fluid was studied after a single 2-gm IV dose of cefotaxime. Peak concentration of 22.8 microgram/ml was obtained after about 80 minutes. The placental passage of cefotaxime after a single 1-gm IV injection also was investigated. Compared with the mother's serum concentration, cord serum concentration was about one fourth and amniotic fluid concentration about one tenth. A maximum concentration of 0.63 microgram/ml was seen in the neonate. Clinical response rates were extremely favorable: 98% against uterine infections, 94% against adnexitis, 91% against pelvic infections, and 93% against external genital infections. Bacteriological effectiveness by pathogen was likewise high, showing eradication rates of 95% against gram-positive aerobes, 88% against gram-negative aerobes, and 96% against gram-negative anaerobes.
D002439:Cefotaxime / Q000378:metabolism / Q000627:therapeutic use*; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008431:Maternal-Fetal Exchange; D008826:Microbial Sensitivity Tests; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000382:microbiology; D013997:Time Factors
D002439:Cefotaxime